MARKET

SCPS

SCPS

SCOPUS BIOPHARMA INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.730
+0.180
+3.96%
Closed 16:00 07/28 EDT
OPEN
4.510
PREV CLOSE
4.550
HIGH
4.880
LOW
4.460
VOLUME
56.86K
TURNOVER
--
52 WEEK HIGH
47.86
52 WEEK LOW
4.460
MARKET CAP
68.60M
P/E (TTM)
-5.9430
1D
5D
1M
3M
1Y
5Y
Scopus Bio names Dr. Alan Horsager as President following acquisition of immunotherapy firm
Scopus BioPharma (SCPS) announces a new appointment following acquisition of immunotherapy company, Olimmune.Alan Horsager, Ph.D., President and CEO of Olimmune, was appointed President of Scopus with responsibility for overseeing the development
Seekingalpha · 07/12 13:01
Scopus BioPharma Names Alan Horsager President Of Co
Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical needs, today announced a new
Benzinga · 07/12 12:37
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 05/27 12:09
60 Biggest Movers From Yesterday
Gainers Lizhi Inc. (NASDAQ: LIZI) shares surged 57.6% to close at $6.84 on Wednesday.
Benzinga · 05/27 09:11
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Benzinga · 05/26 16:54
ASXC, SOL, LPCN and ABCL among midday movers
Gainers: Owens & Minor (OMI) +25%.Express (EXPR) +23%.PDL Community Bancorp (PDLB) +22%.Takung Art (TKAT) +22%.Assertio Holdings (ASRT) +21%.Asensus Surgical (ASXC) +20%.Lizhi (LIZI) +20%.ReneSola (SOL) +19%.Arcimoto (FUV) +18%.Planet Green (PLAG) +16%.Los...
Seekingalpha · 05/26 16:38
41 Stocks Moving In Wednesday's Mid-Day Session
Gainers Asensus Surgical, Inc. (NYSE: ASXC) shares surged 34.4% to $2.7282. HC Wainwright & Co. initiated coverage on Asensus Surgical with a Buy rating and announced a price target of $4.
Benzinga · 05/26 16:25
Asensus Surgical, Nabriva Therapeutics leads healthcare gainers; Larimar Therapeutics, Travere Therapeutics among major losers
Gainers: Asensus Surgical (ASXC) +37%, Nabriva Therapeutics (NBRV) +29%, Kintara Therapeutics (KTRA) +26%, Owens & Minor (OMI) +21%, Protagenic Therapeutics (PTIX) +10%.Losers: Larimar Therapeutics (LRMR) -37%, Travere Therapeutics (TVTX) -17%, Scopus BioP...
Seekingalpha · 05/26 15:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SCPS. Analyze the recent business situations of SCOPUS BIOPHARMA INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SCPS stock price target is 20.00 with a high estimate of 20.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 28
Institutional Holdings: 579.08K
% Owned: 3.99%
Shares Outstanding: 14.50M
TypeInstitutionsShares
Increased
0
0
New
26
568.58K
Decreased
2
1.27K
Sold Out
2
31.28K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.64%
Pharmaceuticals & Medical Research
+1.92%
Key Executives
Chairman/Director
Joshua Lamstein
President/Director
Ashish Sanghrajka
Vice Chairman/Treasurer/Secretary/Director
Robert Gibson
Corporate Executive
Aharon Schwartz
Director
Ira Greenspan
Independent Director
David Battleman
Independent Director
David Buckel
Independent Director
Raphael Hofstein
Independent Director
Paul Hopper
Independent Director
David Weild
No Data
About SCPS
Scopus BioPharma Inc. is a biotechnology company. The Company is focused on developing therapeutics targeting serious diseases. The Company’s lead program targets immuno-oncology gene therapy for the treatment of multiple cancers. Its lead development program is CpG-STAT3siRNA (CO-sTiRNA), which is in Phase I clinical trial, is a STAT3 inhibitor gene therapy. CO-sTiRNA is developed for the treatment of B-cell non-Hodgkins lymphoma. It also stimulates TLR9 receptors to activate the body’s immune defense to kill cancer cells. Its second development program is in pre-clinical stage MRI-1867, a cannabinoid receptor mediating compound for the treatment of systemic sclerosis. MRI-1867 is a small molecule that is an inverse agonist of the cannabinoid-1 receptor (CB1), as well as an inhibitor of the inducible nitric oxide synthase (iNOS) system.

Webull offers kinds of Scopus Biopharma Inc stock information, including NASDAQ:SCPS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCPS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SCPS stock methods without spending real money on the virtual paper trading platform.